Clinical Trial

Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies the how well linaclotide works in treating patients with stages 0-3 colorectal cancer. Linaclotide is a very small protein that binds to receptors on intestinal cells and makes them secrete water and salt.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2026-06-30 -> 2026-09-30 2026-07-23
minor Completion pushed: 2026-06-30 -> 2026-09-30 2026-07-23
notable Enrollment reduced: 230 -> 150 participants 2026-06-25
Trial Details
NCT Number NCT03796884
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators: United States Department of Defense
Conditions Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8 +3 more
Enrollment 150 participants
Start Date 2019-10-30
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22